- Erratum
- Published:
Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
Breast Cancer Research volume 8, Article number: 407 (2006)
The Original Article was published on 07 December 2005
It has been brought to our attention that some paragraphs in the Introduction and Discussion of our recent research article [1] show close similarities to paragraphs in recent publications by Oh et al. [2] and Holloway et al. [3]. While these publications were referenced elsewhere in our paper, the paragraphs which show similarities were not specifically referenced.
We regret this and offer our apologies to the authors.
References
Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research. 2006, 8: R4-10.1186/bcr1366.
Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol. 2001, 15: 1344-1359. 10.1210/me.15.8.1344.
Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B. Mol Endocrinol. 2004, 18: 1396-1410. 10.1210/me.2004-0048.
Author information
Authors and Affiliations
Additional information
The online version of the original article can be found at 10.1186/bcr1366
Rights and permissions
About this article
Cite this article
Munzone, E., Curigliano, G., Rocca, A. et al. Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8, 407 (2006). https://0-doi-org.brum.beds.ac.uk/10.1186/bcr1606
Published:
DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/bcr1606